Jan Poolman
56Patents
11h-index
68Co-inventors
81Inventor score
Filing activity: Dec 29, 1987 → Oct 6, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7118757B1 | Meningococcal class 1 outer-membrane protein vaccine | Emerging Cross-Sectional Technologies | 40 | Expired |
| US5034519A | Oligosaccharides, immunogens and vaccines, and methods for preparing such oligosaccharides, immunogens and vaccines | Human Necessities | 29 | Expired |
| US7628995B2 | Outer membrane vesicles and uses thereof | Chemistry; Metallurgy | 29 | Expired |
| US8703148B2 | Immunogenic composition | Emerging Cross-Sectional Technologies | 25 | Active |
| US5705161A | Immunogenic meningococcal LPS and other membrane vesicles and vaccine therefrom | Human Necessities | 18 | Expired |
| US9486515B2 | Immunogenic composition | Emerging Cross-Sectional Technologies | 15 | Active |
| US7838014B2 | Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB- Neisseria meningitidis | Emerging Cross-Sectional Technologies | 14 | Active |
| US8029807B2 | Outer membrane vesicles and uses thereof | Chemistry; Metallurgy | 11 | Active |
| US9107872B2 | Pneumococcal polysaccharide conjugate vaccine | Emerging Cross-Sectional Technologies | 11 | Active |
| US10583185B2 | Methods and compositions for immune protection against extra-intestinal pathogenic E. coli | Emerging Cross-Sectional Technologies | 11 | Active |
| US8398983B2 | Immunogenic composition | Emerging Cross-Sectional Technologies | 11 | Active |
| US8431136B2 | Immunogenic composition | Emerging Cross-Sectional Technologies | 10 | Active |
| US9884113B2 | Pneumoccal polysacchride conjugate vaccine | Emerging Cross-Sectional Technologies | 10 | Active |
| US9789179B2 | Immunogenic composition | Emerging Cross-Sectional Technologies | 10 | Active |
| US9610339B2 | Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates | Human Necessities | 9 | Active |
| US9610340B2 | Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates | Human Necessities | 9 | Active |
| US8574596B2 | Pertussis antigens and use thereof in vaccination | Emerging Cross-Sectional Technologies | 9 | Active |
| US8883163B2 | Immunogenic composition | Emerging Cross-Sectional Technologies | 8 | Active |
| US9233151B2 | Vaccine composition | Emerging Cross-Sectional Technologies | 7 | Active |
| US8221770B2 | Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB-neisseria meningitidis | Emerging Cross-Sectional Technologies | 7 | Active |
| US11446370B2 | Bioconjugates of E. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof | Emerging Cross-Sectional Technologies | 6 | Active |
| US8679770B2 | Serum bactericidal assay for N. meningitidis specific antisera | Physics | 6 | Active |
| US10279033B2 | Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates | Emerging Cross-Sectional Technologies | 5 | Active |
| US9358279B2 | Immunogenic composition | Emerging Cross-Sectional Technologies | 5 | Active |
| US8163295B2 | Outer membrane vesicles and uses thereof | Chemistry; Metallurgy | 4 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.